San Diego Convention Center

NEC and NTT successfully conduct first-of-its-kind long-distance transmission experiment over 7,000km using 12-core optical fiber

Retrieved on: 
Donnerstag, März 21, 2024
NEC, Internet, Nippon Telegraph and Telephone, Communication, San Diego Convention Center, NTT, Conference, Research, MIMO, Wireless network, Electricity

TOKYO, Mar 22, 2024 - (JCN Newswire) - NEC Corporation (TSE: 6701) and NTT Corporation (NTT) today announced that they have successfully conducted a first-of-its-kind transoceanic-class 7,280km transmission experiment using a coupled 12-core multicore fiber(1), which consists of 12 optical signal transmission paths in a standard outer diameter optical fiber (0.125 mm).

Key Points: 
  • TOKYO, Mar 22, 2024 - (JCN Newswire) - NEC Corporation (TSE: 6701) and NTT Corporation (NTT) today announced that they have successfully conducted a first-of-its-kind transoceanic-class 7,280km transmission experiment using a coupled 12-core multicore fiber(1), which consists of 12 optical signal transmission paths in a standard outer diameter optical fiber (0.125 mm).
  • In order to meet the strong communication demand, there is a growing need to increase transmission capacity per optical submarine cable system in addition to increasing the number of optical submarine cables.Existing optical submarine cables use single-core fiber, which has a single optical transmission path called a core within a single fiber.
  • NEC is currently engaged in a project to install a long-haul optical submarine cable system using two-core multicore fiber with two optical transmission paths.
  • (1) Coupled multicore fiber: An optical fiber in which signals transmitted in each core are separated and demodulated by post-processing on the premise that optical signals leaking from multiple optical transmission paths (cores) in the fiber interfere with and influence each other.

Draganfly to Showcase Cutting-Edge Drone Technologies at XPONENTIAL 2024 in San Diego

Retrieved on: 
Donnerstag, April 11, 2024
Equity, Hearing, Safety, AI, Partnership, San Diego Convention Center, Artificial intelligence, Artificiality, Commander, Colonel, Panel, USAF, Intelligence, Associate, Letter

San Diego, CA., April 11, 2024 (GLOBE NEWSWIRE) -- Draganfly Inc. (NASDAQ: DPRO) (CSE: DPRO) (FSE: 3U8A) (“Draganfly” or the “Company”), an award-winning, industry-leading drone solutions and systems developer is pleased to announce its participation at XPONENTIAL 2024 at booth #3818 in San Diego, CA from April 22nd to April 25th.

Key Points: 
  • San Diego, CA., April 11, 2024 (GLOBE NEWSWIRE) -- Draganfly Inc. (NASDAQ: DPRO) (CSE: DPRO) (FSE: 3U8A) (“Draganfly” or the “Company”), an award-winning, industry-leading drone solutions and systems developer is pleased to announce its participation at XPONENTIAL 2024 at booth #3818 in San Diego, CA from April 22nd to April 25th.
  • The Starling X.2, a product developed in partnership with Promo Drone, will also be presented, offering a glimpse into the future of unmanned aerial communication systems.
  • “Draganfly is thrilled to be at the forefront of the evolving landscape of drone technology and artificial intelligence, as showcased at the Xponential conference,” said Cameron Chell, CEO of Draganfly.
  • “We’re proud to demonstrate the capabilities of our North American-made drone technologies at the San Diego Convention Center, signaling a showcase of our current achievements and a preview of exciting product developments yet to be announced.

Onchilles Pharma Presents at AACR 2024 New Preclinical Data for N17350 and N17465 Demonstrating the Potential for Potent and Tumor-Selective Treatment

Retrieved on: 
Dienstag, April 9, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Cancer, Pharma, Blood, Doxorubicin, Oxaliplatin, Breast, San Diego Convention Center, CDX, Prostate cancer, Death domain, Therapy, Immunogenic cell death, Patient, Neoplasm, ICD, Lung, Toxicity, AACR, Immune system, Carboplatin, Ovarian cancer, CD95, Vaccine

N17350 and N17465 are novel first-in-class oncology programs that harness the potent efficacy of the innate immune system and have the potential to become a major new treatment modality for a wide range of cancer types.

Key Points: 
  • N17350 and N17465 are novel first-in-class oncology programs that harness the potent efficacy of the innate immune system and have the potential to become a major new treatment modality for a wide range of cancer types.
  • Lev Becker, Ph.D., Scientific Founder, Onchilles Pharma, said, “We are excited to unveil systemically delivered N17465 that has the potential to redefine the treatment of solid tumors.
  • The data presented today demonstrate that N17465 exhibits potent and tumor-selective efficacy, mobilizes the immune system for anti-tumor immunity, and produces durable responses in mouse models as a monotherapy.
  • We are confident that N17350 and N17465 represent a novel class of molecules that could become the new foundation of cancer treatment.

RapidFlight Announces Cutting-Edge Mobile Production System

Retrieved on: 
Mittwoch, April 24, 2024
UAV, MPS, Unmanned aerial vehicle, San Diego Convention Center, Intelligence, UAS, AC, Additive, COTS, System

MANASSAS, Va., April 24, 2024 /PRNewswire/ -- RapidFlight, an integrated designer and mass manufacturer of unmanned aircraft systems (UAS), has announced the release of its customer-proven Mobile Production System (MPS). MPS enables the manufacturing and deployment of unmanned aerial vehicles (UAVs) from forward locations. MPS can be owned and operated by RapidFlight, or it can be used by the US Department of Defense (DoD), its allies, and defense contractor primes as an effective way to mass manufacture their UAVs anywhere in the world.

Key Points: 
  • MANASSAS, Va., April 24, 2024 /PRNewswire/ -- RapidFlight , an integrated designer and mass manufacturer of unmanned aircraft systems (UAS), has announced the release of its customer-proven Mobile Production System (MPS).
  • The footprint for this production would be half the size of a standard basketball court and set up in less than one week.
  • "RapidFlight MPS enables deployed production of any UAV platform within a small operational and logistical footprint.
  • "Leveraging MPS, RapidFlight ensures that commanders in the field have the flexibility to respond and adapt to any emergent need with real-time design and the unique ability to scale up production at the edge."

RapidFlight Delivers UAS Innovation, Meeting Replicator Initiative Requirements

Retrieved on: 
Donnerstag, April 18, 2024
Group 3, Gasoline, Technology readiness, Unmanned aerial vehicle, DOD, San Diego Convention Center, EW, UAS, Group 2, Replicator, ISR, 3D printing

MANASSAS, Va., April 18, 2024 /PRNewswire/ -- RapidFlight, a pioneering integrated designer and mass manufacturer of unmanned aircraft systems (UAS), is working with the United States Department of Defense (DoD) in support of the Replicator initiative, which outlines the DOD's plan to field thousands of autonomous systems across multiple warfighting domains.

Key Points: 
  • RapidFlight is immediately capable of producing and delivering thousands of UAVs to the DoD and foreign allies.
  • Following a groundbreaking demonstration at Technology Readiness Experimentation 2023 (TREX23-2) in Camp Atterbury, Indiana, last year, RapidFlight has solidified its position as an industry leader by successfully demonstrating the company's ability to print, assemble, and fly long-range, high-payload unmanned aircraft in support of the Replicator Initiative.
  • RapidFlight's portfolio of UAS solutions, including the versatile E2 UAS , increase mission capability by three to five times when compared to the cost of existing solutions in the market.
  • RapidFlight will be providing a comprehensive view into its technology at XPONENTIAL 2024, booth 4707.

ASQ's World Conference on Quality & Improvement: Creating Lasting Solutions for Individuals, Organizations, and Society

Retrieved on: 
Dienstag, April 16, 2024
Organization, Risk assessment, San Diego Convention Center, Conference, ASQ, Quality, AI

Taking place at the San Diego Convention Center May 12-15, 2024, this year's WCQI promises to be a transformative experience for attendees seeking to enhance their understanding of quality methodologies and prepare for future challenges with sustainable solutions.

Key Points: 
  • Taking place at the San Diego Convention Center May 12-15, 2024, this year's WCQI promises to be a transformative experience for attendees seeking to enhance their understanding of quality methodologies and prepare for future challenges with sustainable solutions.
  • WCQI's agenda includes a diverse range of sessions, workshops, and keynote presentations covering critical areas such as quality management, process improvement, risk assessment, and emerging technologies.
  • Attendees can expect to learn from industry leaders, share best practices, and explore innovative solutions that address the evolving needs of today's business landscape.
  • Working in Harmony with AI, Tuesday, May 14, 8:15 AM PT
    ASQ Fellow and Honorary members will be recognized prior to the keynote address.

Blacksmith Medicines To Highlight Preclinical Oncology Data Demonstrating a Potent and Selective FEN1 Inhibitor Has Synergy with Multiple DDR Drug Classes at AACR Annual Meeting 2024

Retrieved on: 
Mittwoch, April 10, 2024
DNA replication, PARP1, Olaparib, PARG, CRISPR, PARP, HR, IC50, ADME, DNA, Chromatin, PDD, San Diego Convention Center, FEN1, DNA repair, DDR, EC50, Blacksmith, Niraparib, Erosion (morphology), AACR, ATR, Drug discovery, USP1, SAN, Pharmaceutical industry

"Using our metalloenzyme fragment-based drug discovery approach, we have identified a highly potent and selective inhibitor of FEN1 having synergies with multiple DDR drug classes that include inhibitors of PARP, PARG, USP1, and ATR."

Key Points: 
  • "Using our metalloenzyme fragment-based drug discovery approach, we have identified a highly potent and selective inhibitor of FEN1 having synergies with multiple DDR drug classes that include inhibitors of PARP, PARG, USP1, and ATR."
  • The Blacksmith fragment-based drug discovery platform identified a novel metal-binding pharmacophore that binds to the two magnesium ions in the FEN1 active site.
  • Further elaboration using fragment growth strategies resulted in highly potent and selective inhibitors.
  • Title: "Small molecule inhibitor of FEN1 nuclease utilizing a novel metal binding pharmacophore synergizes with inhibitors of USP1, PARP, PARG and ATR"

Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Dienstag, April 9, 2024
Major histocompatibility complex, CPI, Cell, Entrepreneurship, Oncology, Immunotherapy, DLL4, Patient, Neoplasm, Data, Tumor microenvironment, VEGF, Checkpoint, Doctor of Philosophy, MD, Natural killer T cell, News, AACR, MHC, Research and development, Therapy, MHC-I, Antibody, Immune system, PD-L1, San Diego Convention Center, NK, PD-1, Vaccine

Immune responses were generated toward the MHC-I negative tumors by combining CTX-009 with CTX-471.

Key Points: 
  • Immune responses were generated toward the MHC-I negative tumors by combining CTX-009 with CTX-471.
  • The proposed mechanism for this effect suggests the involvement of NK-cells, which can generate potent cell killing independent of MHC-I.
  • Following mCTX-009 and mCTX-471 combination treatment, superior efficacy was observed in MHC Class I negative tumors.
  • A copy of the presentation materials can be accessed on the News & Events section under “ Presentations ” of the Company’s website at www.compasstherapeutics.com once the presentation has concluded.

Cidara Therapeutics Presents Promising New Data on Novel Drug-Fc Conjugate Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2024

Retrieved on: 
Freitag, April 5, 2024
CDTX, Colorectal cancer, Drug, Adenosine, Patient, SAN, Tavarua, AACR, Therapy, Cancer, Pathology, CCR5, CD73, DFC, San Diego Convention Center, Oleclumab, Escape Room, Vaccine

SAN DIEGO, April 05, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, announced the company will deliver four poster presentations, including one late-breaking poster presentation, at this year’s American Association for Cancer Research (AACR) Annual Meeting being held April 5-10, 2024 at the San Diego Convention Center in San Diego, California. The presentations highlight data on the company’s multispecific CD73/PD-1 drug Fc-conjugate (DFC), its CCR5-targeting DFC, and CBO421, its lead oncology DFC candidate targeting CD73.

Key Points: 
  • The presentations highlight data on the company’s multispecific CD73/PD-1 drug Fc-conjugate (DFC), its CCR5-targeting DFC, and CBO421, its lead oncology DFC candidate targeting CD73.
  • “Our Cloudbreak platform has quickly produced DFC candidates effective in preclinical studies across various cancers with specific disease targets.
  • This week, we are sharing data on our CCR5 DFC program for the first time, which has demonstrated robust efficacy as a monotherapy in mouse models of colorectal cancer.
  • Targeting CCR5 has the potential to improve response rates to immune checkpoint inhibitor therapies, which could have a greater impact for patients unresponsive to these current treatment options.

Araris Biotech AG Presents Data on Novel Antibody-Drug Conjugates at American Association for Cancer Research (AACR) Annual Meeting 2024

Retrieved on: 
Freitag, April 5, 2024
Spacecraft, ADC, AACR, San Diego Convention Center, Vaccine

AU ZH, Switzerland, April 05, 2024 (GLOBE NEWSWIRE) -- Araris Biotech AG (“Araris” or “the Company”), a company pioneering a proprietary antibody-drug conjugate (ADC)- technology, today announced the company will deliver two poster presentations, including one late-breaking poster, at this year’s American Association for Cancer Research (AACR) Annual Meeting being held April 5-10, 2024 at the San Diego Convention Center in San Diego, California.

Key Points: 
  • AU ZH, Switzerland, April 05, 2024 (GLOBE NEWSWIRE) -- Araris Biotech AG (“Araris” or “the Company”), a company pioneering a proprietary antibody-drug conjugate (ADC)- technology, today announced the company will deliver two poster presentations, including one late-breaking poster, at this year’s American Association for Cancer Research (AACR) Annual Meeting being held April 5-10, 2024 at the San Diego Convention Center in San Diego, California.
  • The presentations highlight preclinical data on two novel dual TOP1i antibody-drug conjugates (ADCs) generated using Araris’ proprietary ADC conjugation technology and linker platform.
  • “The preclinical data highlighted in our presentations at this year’s AACR meeting demonstrate the potential of novel dual TOP1i ADCs, generated using two TOP1i payloads, each with differing properties that help improve efficacy and tolerability of the ADC,” said Philipp Spycher, Ph.D., co-founder and chief scientific officer of Araris Biotech AG.
  • “We’re excited by the promise of combining these payloads in various ADCs, along with a stable attachment using our conjugation technology, to create therapeutic options with potentially superior inhibition of tumor growth for patients.”
    Presentation details are summarized below:
    Abstract Title: Novel dual TOP1i ADC inducing superior tumor growth inhibition at low-drug load vs. trastuzumab deruxtecan
    In mouse PK studies, the excellent in vitro stability of the ADC was confirmed with no signs of payload loss or linker-cleavage, and the ADC showed mAb-like exposure to maximize payload delivery
    In head-to-head study vs T-DXd using a HER2-expressing breast cancer model, Araris’ ADC showed superior anti-tumor efficacy compared to T-DXd
    Generated an anti-NaPi2b ADC with two TOP1i payloads that have different properties, designed to maximize tumor-specific activity
    Showed excellent stability in mouse and human sera without payload deconjugation or linker cleavage, as well as stability in circulation, high anti-tumor activity, and mAb-like PK exposure to maximize payload delivery